Cargando…
CD276 as a Candidate Target for Immunotherapy in Medullary Thyroid Cancer
Medullary thyroid cancer (MTC) is a rare malignancy, and the treatment of metastatic MTC is challenging. In previous work, immune profiling (RNA-Seq) of MTC identified CD276 as a potential target for immunotherapy. CD276 expression was 3-fold higher in MTC cells than in normal tissues. Paraffin bloc...
Autores principales: | Hińcza-Nowak, Kinga, Kowalik, Artur, Walczyk, Agnieszka, Pałyga, Iwona, Gąsior-Perczak, Danuta, Płusa, Agnieszka, Kopczyński, Janusz, Chrapek, Magdalena, Góźdź, Stanisław, Kowalska, Aldona |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10298428/ https://www.ncbi.nlm.nih.gov/pubmed/37373167 http://dx.doi.org/10.3390/ijms241210019 |
Ejemplares similares
-
Immune Profiling of Medullary Thyroid Cancer—An Opportunity for Immunotherapy
por: Hińcza-Nowak, Kinga, et al.
Publicado: (2021) -
Histopathology and immunohistochemistry as prognostic factors for poorly differentiated thyroid cancer in a series of Polish patients
por: Walczyk, Agnieszka, et al.
Publicado: (2020) -
Immunohistochemistry cannot replace DNA analysis for evaluation of BRAF V600E mutations in papillary thyroid carcinoma
por: Szymonek, Monika, et al.
Publicado: (2017) -
Does the TT Variant of the rs966423 Polymorphism in DIRC3 Affect the Stage and Clinical Course of Papillary Thyroid Cancer?
por: Hińcza, Kinga, et al.
Publicado: (2020) -
Are molecular tests necessary to diagnose NIFTP?
por: Kuchareczko, Artur, et al.
Publicado: (2021)